Scholarlink

<p>Behçet’s disease (BD) is a systemic inflammatory disorder characterized by mucocutaneous ulceration, uveitis, and variable articular, neurological, gastrointestinal, and vascular involvement. BD pathogenesis is multifactorial, involving genetic susceptibility, immune dysregulation, and environmental triggers. Curcumin, a bioactive compound of <i>Curcuma longa</i>, has anti-inflammatory, antioxidant, and immunomodulatory properties. The aim of this study is to review clinical and experimental evidence on the potential therapeutic role of curcumin in BD. Database searches up to November 2025 identified three studies, including two clinical and one experimental. Experimental study demonstrated reduced interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) expression with curcumin, while clinical findings showed that nanocurcumin decreased disease activity, enhanced regulatory T cell (Treg) markers, and suppressed T helper 17 (Th17)-related cytokines and transcription factors. Although findings suggest potential therapeutic benefit, evidence for curcumin in BD remains limited, warranting larger, well-designed studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Curcumin in Behçet’s disease: exploring therapeutic potential, evidence, and key research gaps

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Zinat Heidari,
  • Zahra Jahani,
  • Maryam Sahebari,
  • Zahra Mirfeizi,
  • Elham Atabati,
  • Prashant Kesharwani,
  • Amirhossein Sahebkar

摘要

Behçet’s disease (BD) is a systemic inflammatory disorder characterized by mucocutaneous ulceration, uveitis, and variable articular, neurological, gastrointestinal, and vascular involvement. BD pathogenesis is multifactorial, involving genetic susceptibility, immune dysregulation, and environmental triggers. Curcumin, a bioactive compound of Curcuma longa, has anti-inflammatory, antioxidant, and immunomodulatory properties. The aim of this study is to review clinical and experimental evidence on the potential therapeutic role of curcumin in BD. Database searches up to November 2025 identified three studies, including two clinical and one experimental. Experimental study demonstrated reduced interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) expression with curcumin, while clinical findings showed that nanocurcumin decreased disease activity, enhanced regulatory T cell (Treg) markers, and suppressed T helper 17 (Th17)-related cytokines and transcription factors. Although findings suggest potential therapeutic benefit, evidence for curcumin in BD remains limited, warranting larger, well-designed studies.